Table 4.
Unadjusted and adjusted relative hazards of the composite of the initiation of invasive mechanical ventilation or death
|
Unadjusted analysis |
Adjusted analysis* |
Adjusted analysis† |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Overall (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any) | 0·60 (0·43–0·84) | 0·0030 | 0·64 (0·45–0·91) | 0·012 | 0·61 (0·40–0·92) | 0·020 |
| Tocilizumab (any)‡ | 0·54 (0·37–0·78) | 0·0009 | .. | .. | 0·53 (0·31–0·89)§ | 0·016 |
| Baseline PaO2/FiO2≤150 mm Hg (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any)¶ | 0·30 (0·17–0·52) | .. | 0·20 (0·11–0·36) | .. | 0·19 (0·08–0·44) | .. |
| Interaction p value ¶ | .. | .. | .. | .. | .. | 0·011 |
| Baseline PaO2/FiO2>150 mmHg (two-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Tocilizumab (any)¶ | 0·31 (0·16–0·59) | .. | 0·39 (0·20–0·77) | .. | 0·46 (0·21–0·99) | .. |
| Overall comparison (three-way contrast) | ||||||
| Standard of care | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Subcutaneous tocilizumab | 0·63 (0·41–0·97) | 0·036 | 0·69 (0·44–1·08) | 0·102 | 0·65 (0·39–1·11) | 0·11 |
| Intravenous tocilizumab | 0·57 (0·36–0·90) | 0·016 | 0·60 (0·38–0·95) | 0·030 | 0·55 (0·31–0·98) | 0·042 |
| Intravenous tocilizumab | 1 (ref) | .. | 1 (ref) | .. | 1 (ref) | .. |
| Subcutaneous tocilizumab | 1·10 (0·61–1·95) | 0·76 | 1·14 (0·63–2·05) | 0·67 | 1·18 (0·59–2·36) | 0·64 |
| Standard of care | 1·75 (1·11–2·75) | 0·016 | 1·66 (1·05–2·62) | 0·030 | 1·80 (1·02–3·19) | 0·042 |
Data are n (95% CI) unless otherwise indicated. Data obtained using a Cox regression model. 152 patients with missing PaO2/FiO2 were not included in the stratified analysis. PaO2/FiO2=ratio of arterial oxygen partial pressure to fractional inspired oxygen.
Adjusted for age, sex, and recruiting centre.
Adjusted for age, sex, recruiting centre, duration of symptoms, and Subsequent Organ Failure Assessment (SOFA) score.
Using a weighted Cox instead of standard Cox model.
Adjusted for age, sex, recruiting centre, duration of symptoms, SOFA score, use of steroids after baseline, and censoring using inverse probability weighting.
Some p values intentionally left out as p values in the subsets are not interpretable.